Literature DB >> 34793974

Dichotomous effects of cellular expression of STAT3 on tumor growth of HNSCC.

Thomas E Bickett1, Michael W Knitz1, Miles Piper1, Ayman J Oweida2, Jacob Gadwa1, Laurel B Darragh3, Diemmy Nguyen1, Shilpa Bhatia1, Shiv Bhuvane1, Andy V Phan1, Benjamin Van Court1, Sophia Corbo1, Tiffany Pham4, Alexander L Dent5, Laurel Lenz6, Sana D Karam7.   

Abstract

STAT3 signaling has been shown to regulate cellular function and cytokine production in the tumor microenvironment (TME). Within the head and neck squamous cell carcinoma (HNSCC) TME, we previously showed that therapeutic targeting of STAT3 in combination with radiation resulted in improved tumor growth delay. However, given the independent regulatory effects STAT3 has on anti-tumor immunity, we aimed to decipher the effects of individually targeting STAT3 in the cancer cell, regulatory T cells (Tregs), and natural killer (NK) cell compartments in driving tumor growth and resistance to therapy in HNSCCs. We utilized a CRISPR knockout system for genetic deletion of STAT3 within the cancer cell as well as two genetic knockout mouse models, FoxP3-Cre/STAT3 fl and NKp46-Cre/STAT3 fl, for Tregs and NK cell targeting, respectively. Our data revealed differences in development of resistance to treatment with STAT3 CRISPR knockout in the cancer cell, driven by differential recruitment of immune cells. Knockout of STAT3 in Tregs overcomes this resistance and results in Treg reprogramming and recruitment and activation of antigen-presenting cells. In contrast, knockout of STAT3 in the NK cell compartment results in NK cell inactivation and acceleration of tumor growth. These data underscore the complex interplay between the cancer cell and the immune TME and carry significant implications for drug targeting and design of combination approaches in HNSCCs.
Copyright © 2021 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  NK cells; STAT3; head and neck squamous cell carcinoma; radiation therapy; regulatory T cells

Mesh:

Substances:

Year:  2021        PMID: 34793974      PMCID: PMC8899526          DOI: 10.1016/j.ymthe.2021.11.011

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  51 in total

1.  The murine homologue of the human NKp46, a triggering receptor involved in the induction of natural cytotoxicity.

Authors:  R Biassoni; A Pessino; C Bottino; D Pende; L Moretta; A Moretta
Journal:  Eur J Immunol       Date:  1999-03       Impact factor: 5.532

2.  Prognostic significance of nuclear pSTAT3 in oral cancer.

Authors:  Muzafar A Macha; Ajay Matta; Jatinder Kaur; S S Chauhan; Alok Thakar; Nootan K Shukla; Siddhartha Datta Gupta; Ranju Ralhan
Journal:  Head Neck       Date:  2011-04       Impact factor: 3.147

3.  IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo.

Authors:  Emmanuel Zorn; Erik A Nelson; Mehrdad Mohseni; Fabrice Porcheray; Haesook Kim; Despina Litsa; Roberto Bellucci; Elke Raderschall; Christine Canning; Robert J Soiffer; David A Frank; Jerome Ritz
Journal:  Blood       Date:  2006-04-27       Impact factor: 22.113

4.  Interferon-γ Drives Treg Fragility to Promote Anti-tumor Immunity.

Authors:  Abigail E Overacre-Delgoffe; Maria Chikina; Rebekah E Dadey; Hiroshi Yano; Erin A Brunazzi; Gulidanna Shayan; William Horne; Jessica M Moskovitz; Jay K Kolls; Cindy Sander; Yongli Shuai; Daniel P Normolle; John M Kirkwood; Robert L Ferris; Greg M Delgoffe; Tullia C Bruno; Creg J Workman; Dario A A Vignali
Journal:  Cell       Date:  2017-05-25       Impact factor: 41.582

5.  Targeting Treg-Expressed STAT3 Enhances NK-Mediated Surveillance of Metastasis and Improves Therapeutic Response in Pancreatic Adenocarcinoma.

Authors:  Miles Piper; Benjamin Van Court; Adam Mueller; Shuichi Watanabe; Thomas Bickett; Shilpa Bhatia; Laurel B Darragh; Max Mayeda; Diemmy Nguyen; Jacob Gadwa; Michael Knitz; Sophia Corbo; Rustain Morgan; Jung-Jae Lee; Alexander Dent; Karyn Goodman; Wells Messersmith; Richard Schulick; Marco Del Chiaro; Yuwen Zhu; Ross M Kedl; Laurel Lenz; Sana D Karam
Journal:  Clin Cancer Res       Date:  2022-03-01       Impact factor: 13.801

6.  Transcription of the activating receptor NKG2D in natural killer cells is regulated by STAT3 tyrosine phosphorylation.

Authors:  Shiguo Zhu; Prasad V Phatarpekar; Cecele J Denman; Vladimir V Senyukov; Srinivas S Somanchi; Hoainam T Nguyen-Jackson; Emily M Mace; Alexandra F Freeman; Stephanie S Watowich; Jordan S Orange; Steven M Holland; Dean A Lee
Journal:  Blood       Date:  2014-06-02       Impact factor: 22.113

7.  Inhibition of WEE1 kinase and cell cycle checkpoint activation sensitizes head and neck cancers to natural killer cell therapies.

Authors:  Jay Friedman; Megan Morisada; Lillian Sun; Ellen C Moore; Michelle Padget; James W Hodge; Jeffrey Schlom; Sofia R Gameiro; Clint T Allen
Journal:  J Immunother Cancer       Date:  2018-06-21       Impact factor: 13.751

Review 8.  Chemokines Modulate Immune Surveillance in Tumorigenesis, Metastasis, and Response to Immunotherapy.

Authors:  Anna E Vilgelm; Ann Richmond
Journal:  Front Immunol       Date:  2019-02-27       Impact factor: 7.561

9.  Eomes-Dependent Loss of the Co-activating Receptor CD226 Restrains CD8+ T Cell Anti-tumor Functions and Limits the Efficacy of Cancer Immunotherapy.

Authors:  Marianne Weulersse; Assia Asrir; Andrea C Pichler; Lea Lemaitre; Matthias Braun; Nadège Carrié; Marie-Véronique Joubert; Marie Le Moine; Laura Do Souto; Guillaume Gaud; Indrajit Das; Elisa Brauns; Clara M Scarlata; Elena Morandi; Ashmitha Sundarrajan; Marine Cuisinier; Laure Buisson; Sabrina Maheo; Sahar Kassem; Arantxa Agesta; Michaël Pérès; Els Verhoeyen; Alejandra Martinez; Julien Mazieres; Loïc Dupré; Thomas Gossye; Vera Pancaldi; Camille Guillerey; Maha Ayyoub; Anne S Dejean; Abdelhadi Saoudi; Stanislas Goriely; Hervé Avet-Loiseau; Tobias Bald; Mark J Smyth; Ludovic Martinet
Journal:  Immunity       Date:  2020-10-13       Impact factor: 43.474

Review 10.  Targeting STAT3 in Cancer Immunotherapy.

Authors:  Sailan Zou; Qiyu Tong; Bowen Liu; Wei Huang; Yan Tian; Xianghui Fu
Journal:  Mol Cancer       Date:  2020-09-24       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.